Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Deferred Revenue (2016 - 2019)

Ultragenyx Pharmaceutical has reported Current Deferred Revenue over the past 5 years, most recently at $69000.0 for Q1 2019.

  • Quarterly Current Deferred Revenue fell 90.46% to $69000.0 in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $69000.0 through Mar 2019, down 90.46% year-over-year, with the annual reading at $6.0 million for FY2017, 1655.43% up from the prior year.
  • Current Deferred Revenue was $69000.0 for Q1 2019 at Ultragenyx Pharmaceutical, down from $1.2 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $6.0 million in Q4 2017 and troughed at $69000.0 in Q1 2019.
  • The 5-year median for Current Deferred Revenue is $489000.0 (2016), against an average of $958500.0.
  • Year-over-year, Current Deferred Revenue soared 1655.43% in 2017 and then crashed 90.46% in 2019.
  • A 5-year view of Current Deferred Revenue shows it stood at $192000.0 in 2015, then skyrocketed by 77.6% to $341000.0 in 2016, then soared by 1655.43% to $6.0 million in 2017, then tumbled by 79.22% to $1.2 million in 2018, then tumbled by 94.45% to $69000.0 in 2019.
  • Per Business Quant, the three most recent readings for RARE's Current Deferred Revenue are $69000.0 (Q1 2019), $1.2 million (Q2 2018), and $723000.0 (Q1 2018).